Skip to main content

Table 1 The clinical and MRI characteristics of patients (n = 12)

From: Application of first-order feature analysis of DWI-ADC in rare malignant mesenchymal tumours of the maxillofacial region

MR1 scan

Sex

Age

Region

ADC valuc (l0 3 mm2/s)

Pathological and IHC

Patient 1

F

26

Zygoma

1.12

spindie shaped tumor cells and scattered in trabecular bone tissue and bone like matrix tissue; Ki-67 (10–20%), CK (−), SMA and CD99 (+)

Patient 2

F

40

Jaw

1.56

a large number of chondrocytes with obvious heteromorphism and bone septum; viaentin (+), S-100 and CK (−), Ki-67(60%)

Patient 3

M

56

Jaw

1.54

A large number of chondrocytes; S-100(−), Viacntin(+), CK(−), Ki-67(50%)

Patient 4

M

85

Neck

1.25

A large number of spindle cells arranged in bundles or vortices, and the cells were slightly deformed, with visible nuclei and mitotic images; viaentin (+), S-100 and CK (−), Ki-67(30%)

Patient 5

F

62

Jaw

1.36

A large number of spindle cells; Ki-67(10–20%), CK(−), SMA (+)

Patient 6

F

59

Jaw

1.55

a large number of chondrocytes with obvious heteromorphism and bone septum; viaentin (+), Ki-67(30%)

Patient 7

F

62

Buccal

0.56

Lymphoid hyperplasia; PCK(−), EMA(−), CD20(+), CD79a(+), PAX-5(+), CD3(−), CD38(+), CyclinDI(−), MUMl(−), CD30(−), CD 10(+), Bcl-6(−), Bcl-2(−), CD23(−), CD5(+), Ki67(70%)

Patient 8

M

85

Tongue

0.31

Lymphoid hyperplasia, destroyed lymphoid follicles structure; CD3T(+), BCL-6(−), BCL-2(+), CD 10(−), cyclinDl(−), CD79a(+), Pan-5(+), kappa(−), Ki-67(< 10%)

Patient 9

M

56

Parotid gland

0.37

Lymphoid hyperplasia with obvious heteromorphism; CD3(+), CD20(+), BCL-2(+), BCL-6(+), CD 10(+), Muml(+), PAX-5(+), CD79a(+), Ki-67(70 -80%)

Patient 10

M

67

Parotid gland

0.54

Lymphoid hyperplasia, tumor cells infiltrated glands in some areas, serous acini and adipose tissue display; CD20(+), CD 10 (+), CD3 partial cells (+), CD21 showed FDC network, BCL-6 (+), BCL-2 (+), CD38 germinal center positive (+)

Patient 11

M

13

Parotid gland

0.57

Lymphoid hyperplasia, CD3T(+), CD10(−), BCL-6(+), BCL-2(+), CD79a(+), Ki-67(40–50%)

Patient 12

M

40

Buccal

0.61

Lymphoid hyperplasia, CD3T(+), CD20(−), CD10(−), BCL-6(+), BCL-2(+), CD3 partial cells (+), Ki-67(20%)